Predictive Biomarkers of Adjuvant Trastuzumab in the HER2+N9831 Intergroup Trial

HER2 N9831 组间试验中曲妥珠单抗辅助治疗的预测生物标志物

• 批准号: 7804608
• 负责人: EDITH A. PEREZ
• 金额: $ 19.82万
• 依托单位: MAYO CLINIC JACKSONVILLE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-20 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7804608
• 关键词: Address; Adjuvant; Adverse effects; Antibodies; Arts; Biological Assay; Biological Markers; Breast; Breast Cancer Treatment; Cancer Patient; Caring; Chromosomes; Clinical; Clinical Trials; Complementary DNA; Correlative Study; Custom; Cyclophosphamide; DNA; DNA topoisomerase II alpha; Data; Disease; Disease-Free Survival; Doxorubicin; ERBB2 gene; ERBB3 gene; Enrollment; Epidermal Growth Factor Receptor; ErbB4 gene; Family; Fluorescent in Situ Hybridization; Formalin; Gene Expression; Gene Expression Profiling; Gene Proteins; Genes; Genetic; Goals; Human; Immunohistochemistry; Individual; Insulin-Like-Growth Factor I Receptor; Investigation; Ligation; Mammary Neoplasms; Mediating; Medicine; Methods; North Central Cancer Treatment Group; PTEN gene; Paclitaxel; Paraffin Embedding; Paraffin Tissue; Patient Care; Patients; Pattern; Phase; Positive Lymph Node; Primary Neoplasm; Proteins; RNA; Recombinants; Recurrence; Resected; Resistance; Reverse Transcriptase Polymerase Chain Reaction; Risk; Sampling; Signal Pathway; Specimen; System; TOP2A gene; Technology; Testing; Therapeutic Intervention; Time; TimeLine; Tissues; Toxic effect; Trastuzumab; Tumor Markers; Variant; Woman; base; clinical care; design; experience; follow-up; high risk; humanized monoclonal antibodies; improved; malignant breast neoplasm; multidisciplinary; patient population; pre-clinical; protein expression; public health relevance; response; translational study; treatment response; tumor; validation studies

DESCRIPTION (provided by applicant): Successful personalized care of breast cancer patients is critically dependent on accurately applying predictive markers of treatment response. The specific objective of this proposal is to identify reliable biomarkers, derived from proteins, DNA aberrations, and gene expression patterns, in paraffin-embedded primary breast tumors that predict response to adjuvant trastuzumab (an antibody directed against HER2). These patients were enrolled in the landmark NCCTG-sponsored adjuvant N9831intergroup trial (EA Perez-PI) that led to dramatic changes in the clinical care of HER2-positive breast cancer patients. Our overall hypothesis is that tissue markers associated with EGF-family signaling pathways will predict those patients more likely to respond to adjuvant trastuzumab. Our specific aims include three translational studies: 1) To determine the tissue expression of select proteins involved in the mechanisms of trastuzumab activity and resistance using conventional immunohistochemistry and Automated Quantitative Analysis (AQUA); 2) To determine DNA aberrations of specific genes that have been suggested to be associated with trastuzumab response using fluorescence in situ hybridization; and 3) To identify gene expression patterns predictive of trastuzumab benefit using DASL, a gene expression profiling system specifically designed for paraffin tissue. Our multidisciplinary team has the experience to accomplish these important translational protein- and gene-based studies within the proposed timeline. We have collected all relevant specimens to conduct this investigation as well as the clinical follow-up data related to disease free and overall survival. Results from these correlative studies using the well-defined N9831 patient population will provide a better understanding of individual variation of benefit to adjuvant trastuzumab and will identify opportunities for therapeutic intervention for patients at increased risk of recurrence. As this is achieved, it will be possible to more effectively tailor therapy with the greatest efficiency and fewest side effects. Positive results from these proposed correlative studies will also allow us to design further phase II and III clinical trials addressing our overall goal of individualized therapy for patients with breast cancer. PUBLIC HEALTH RELEVANCE: Biomarker identification and validation studies are necessary to successfully achieve personalized medicine. This is critically important in the adjuvant management of patients with resected HER2-positive breast cancer as trastuzumab treatment significantly increases disease free and overall survival, but is associated with potential toxicities. Our study proposes biomarker tissue correlative studies to help identify those patients most likely to benefit from this treatment.

描述（由申请人提供）：乳腺癌患者成功的个性化护理关键依赖于准确应用治疗反应的预测标记。本提案的具体目标是鉴定可靠的生物标志物，来源于石蜡包埋的原发性乳腺肿瘤中的蛋白质、DNA畸变和基因表达模式，以预测对曲妥珠单抗（一种针对HER2的抗体）的反应。这些患者参加了具有里程碑意义的ncctg赞助的辅助剂n9831组间试验（EA Perez-PI），该试验导致her2阳性乳腺癌患者的临床护理发生了巨大变化。我们的总体假设是，与egf家族信号通路相关的组织标志物将预测那些更有可能对辅助曲妥珠单抗有反应的患者。我们的具体目标包括三项转化研究：1)使用常规免疫组织化学和自动定量分析（AQUA）确定参与曲妥珠单抗活性和耐药机制的选定蛋白的组织表达；2)利用荧光原位杂交技术确定与曲妥珠单抗应答相关的特定基因的DNA畸变；3)使用DASL（一种专门为石蜡组织设计的基因表达谱系统）鉴定预测曲妥珠单抗获益的基因表达模式。我们的多学科团队拥有丰富的经验，能够在规定的时间内完成这些重要的翻译蛋白和基因研究。我们收集了所有相关标本进行调查，并收集了与无病生存期和总生存期相关的临床随访资料。使用定义明确的N9831患者群体的相关研究结果将更好地了解辅助曲妥珠单抗获益的个体差异，并将为复发风险增加的患者确定治疗干预的机会。随着这一目标的实现，将有可能以最大的效率和最小的副作用更有效地定制治疗。这些相关研究的积极结果也将使我们能够设计进一步的II期和III期临床试验，以实现我们对乳腺癌患者个体化治疗的总体目标。